Biopharmaceutical Pipeline

Alzheimer’s Disease

5.7 Million

Americans who suffer with Alzheimers Disease

14 Million

Americans who will suffer with Alzheimers Disease by 2050

$25 Billion

Total Addressable Market by 2027